Delighted to present these data today from the DETERMINE trials at the #ESCCongress The first evidence of a beneficial effect of a HF therapy on accelerometer-based measures of physical activity. A promising new outcome measure for HF trials.

40th Anniversary TIMI Book timi.org/40th-anniversa… Proud to have contributed to lesson number 1 having invented the TIMI frame count and TIMI Perfusion grade and contributed to the open artery and open microvasculature hypothesis #ESCCongress via TIMI Study Group

Thrilled to present the results from the WITHDRAW-AF randomized clinical trial at #ESC2024 - low LVSD relapse rates in recovered AFCM following withdrawal of HF pharmacotherapy Baker Institute University of Melbourne Heart Centre at the Alfred European Society of Cardiology John Mandrola, MD

Vericiguat in worsening HF - The 5th pillar Great presentation by clara saldarriaga 📌Vericiguat reduced the risk of HFH or CV death 📌No significant changes in renal function over time 📌No excessive BP reductions — Vericiguat en worsening heart failure 📌 Vericiguat reduce

🔥RESHAPE-HF 2 published in NEJM met all 3 primary endpoints 📌 Median EROA 0.23, 56% grade 3+ MR 📌⬇️ 36% in CV death and HHF within 24 m 📌⬇️ 41% Recurrent HHF within 24 m 📌⬆️ 11 points KCCQ-OS 📌MitraClip in ⬇️ severe FMR needs further study nejm.org/doi/full/10.10…

Tri-fr trial: Multicentric randomised eval of TEER in Tx of severe isolated secondary tricuspid regurgitation #ESCCongress #LBCT #ESCHotline 📍1st trial of TR 📍composite primary endpoint: Composite score 📍 >50% 💃🏻👏🏽👏🏽, not frail because good 6MW 📍TEER group better outcome

#ESCCongressVisuals from Hotline 3 Tri .fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation MATTERHORN - Transcatheter versus surgical mitral valve repair in patients with

Loss of kidney function accelerates dramatically after HF, while atherosclerotic & HF risk increases 3-4 fold after CKD progression Highlighting epidemiological & therapeutic synergies between CKD & CV disease Cardio-kidney-metabolic #simpub for #ESCCongress in JACC Journals

Pooled data from ~15,000 pts in 4-RCTs examining the relationship b/w NT-proBNP, kidney function & outcomes in HFpEF Data which calls into question proposals for higher NT-proBNP references ranges in people with CKD #Simpub in JACC-HF for #ESCCongress sciencedirect.com/science/articl…

Ischemia analysis of REVIVED #ESCCongress 💜 approx 20% of LV scarred 30% ischemic on CMR 🏥 very high rates of death or aborted sudden death 📈 amount of ischemia not associated with risk of events 📈 no benefit of PCI whether ischemia extensive or mild/moderate

#ESCCongressVisuals for Hotline 5 POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI? NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation RHEIA - Transcatheter versus surgical aortic

🚨FINEARTS-HF trial! 📌Finerenone in HFmrEF and HFpEF ☑️Finerenone reduced the composite endpoint of CV death and total HF events ☑️Consistent results among subgroups ☑️More hyperkalemia with Finerenone — 🚨Estudio FINEARTS-HF 📌Finerenona en IC levemente reducida y

Excited to share the groundbreaking results of the 5 years follow-up of the #AVATAR trial in asymptomatic patients with severe AS and normal LVEF...Published simultaneously in the #EHJ and just presented during LBCT session at the European Society of Cardiology congress!

The SENIOR-RITA trial found that an invasive strategy involving coronary revascularization plus medical therapy did not significantly reduce the risk of cardiovascular death or nonfatal myocardial infarction compared to a conservative medical therapy approach in older patients

SENIOR RITA presentation by Professor Vijay Kunadian It's an almost impossible to do study and congratulations! No changes of composite end point and CV death but reduced repeat mi or readmission. #ESCCongress2024

#ESC2024 European Society of Cardiology FAME 2: 10-year follow-up 🏪 PCI is 25% more likely to lead to better outcomes than medical therapy alone 🔑 48% of patients were tied. Nearly half the time, it won't make a big difference which one you choose. PCRonline 🫀 CoreAalst OLV HartcentrumAalst Optima Education

Fascinating talks using pooled data from REVIVED (R) + STICH (S) ➡️ R patients had higher baseline surgical risk ➡️ No difference in tx effect in either trial by surgical risk ➡️ S-OMT arm had worse outcomes than R-OMT ➡️ R-OMT arm had better outcomes than S-CABG! #ESCCongress

Illuminating debate on re vascularisation with great points from Divaka Perera - interesting perspective that it is myocardial scar rather than ischaemia burden driving death rates

Well done to Rajdip Dulai for his excellent study and results of #SHAMPVI 👏🏾 Great work from EssexCTC

#ESCCongress2024 **MATTERHORN Trial** RCT of mitral transcatheter edge-edge repair (mTEER) versus MV surgery in patients with HFrEF and at least moderate secondary MR A thread...